NCT05198934 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 54
- group Id
- BG001
- value
- 53
- group Id
- BG002
- value
- 53
- group Id
- BG003
- value
- 160
- units
- Participants
- groups
- description
- Participants received investigator's choice of trifluridine and tipiracil or regorafenib. Treatment continued until progressive disease, intolerance to treatment necessitating treatment discontinuation, need for other anticancer therapy, withdrawal of consent, or death.
- id
- BG000
- title
- Trifluridine and Tipiracil or Regorafenib
- description
- Participants received sotorasib 240 mg QD in combination with panitumumab. Treatment continued until progressive disease, intolerance to treatment necessitating treatment discontinuation, need for other anticancer therapy, withdrawal of consent, or death.
- id
- BG001
- title
- Sotorasib 240 mg + Panitumumab
- description
- Participants received sotorasib 960 mg QD in combination with panitumumab. Treatment continued until progressive disease, intolerance to treatment necessitating treatment discontinuation, need for other anticancer therapy, withdrawal of consent, or death.
- id
- BG002
- title
- Sotorasib 960 mg + Panitumumab
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 11.7
- value
- 61.5
- group Id
- BG001
- spread
- 11.9
- value
- 58.2
- group Id
- BG002
- spread
- 11.6
- value
- 60.9
- group Id
- BG003
- spread
- 11.7
- value
- 60.2
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 30
- group Id
- BG001
- value
- 27
- group Id
- BG002
- value
- 24
- group Id
- BG003
- value
- 81
- title
- Female
- measurements
- group Id
- BG000
- value
- 24
- group Id
- BG001
- value
- 26
- group Id
- BG002
- value
- 29
- group Id
- BG003
- value
- 79
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 12
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 45
- group Id
- BG001
- value
- 53
- group Id
- BG002
- value
- 47
- group Id
- BG003
- value
- 145
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 3
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 22
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 40
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 37
- group Id
- BG001
- value
- 30
- group Id
- BG002
- value
- 42
- group Id
- BG003
- value
- 109
- title
- White
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 10
- title
- Other/Unknown
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- Full analysis set (FAS) included all randomized participants.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 54
- group Id
- BG001
- value
- 53
- group Id
- BG002
- value
- 53
- group Id
- BG003
- value
- 160
- units
- Participants
- groups
- description
- Participants received investigator's choice of trifluridine and tipiracil or regorafenib. Treatment continued until progressive disease, intolerance to treatment necessitating treatment discontinuation, need for other anticancer therapy, withdrawal of consent, or death.
- id
- BG000
- title
- Trifluridine and Tipiracil or Regorafenib
- description
- Participants received sotorasib 240 mg QD in combination with panitumumab. Treatment continued until progressive disease, intolerance to treatment necessitating treatment discontinuation, need for other anticancer therapy, withdrawal of consent, or death.
- id
- BG001
- title
- Sotorasib 240 mg + Panitumumab
- description
- Participants received sotorasib 960 mg QD in combination with panitumumab. Treatment continued until progressive disease, intolerance to treatment necessitating treatment discontinuation, need for other anticancer therapy, withdrawal of consent, or death.
- id
- BG002
- title
- Sotorasib 960 mg + Panitumumab
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 11.7
- value
- 61.5
- group Id
- BG001
- spread
- 11.9
- value
- 58.2
- group Id
- BG002
- spread
- 11.6
- value
- 60.9
- group Id
- BG003
- spread
- 11.7
- value
- 60.2
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 30
- group Id
- BG001
- value
- 27
- group Id
- BG002
- value
- 24
- group Id
- BG003
- value
- 81
- title
- Female
- measurements
- group Id
- BG000
- value
- 24
- group Id
- BG001
- value
- 26
- group Id
- BG002
- value
- 29
- group Id
- BG003
- value
- 79
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 12
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 45
- group Id
- BG001
- value
- 53
- group Id
- BG002
- value
- 47
- group Id
- BG003
- value
- 145
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 3
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 22
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 40
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 37
- group Id
- BG001
- value
- 30
- group Id
- BG002
- value
- 42
- group Id
- BG003
- value
- 109
- title
- White
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 10
- title
- Other/Unknown
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- Full analysis set (FAS) included all randomized participants.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Independent clinical review pending · Not medical advice
Triangle